Are inactivation procedures for blood products good or bad?BMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7372.1116/b (Published 09 November 2002) Cite this as: BMJ 2002;325:1116
- Gregor Caspari, head, transfusion unit (firstname.lastname@example.org)
- Institut für Transfusionsmedizin, 14770 Brandenburg an der Havel, Germany
EDITOR—In their report on recent developments in transfusion medicine, Regan and Taylor mention that, in future, infectious diseases transmitted by cellular blood products might be prevented by inactivation procedures.1 All pathogen inactivation procedures for cellular blood products involve one step, and failure cannot be compensated by a second step.
Owing to technical constraints, validation of procedures is limited to five to seven logs. Without screening (or a virus carrier escaping the screening process), however, a platelet concentrate from a …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial